This article originally appeared on MyCentralJersey.com: Global pharmaceutical firm chooses Bridgewater for new corporate offices BRIDGEWATER – Gov. Phil Murphy attended the opening of corporate offices for an international pharmaceutical company in the Somerset Corporate Center.

Aging populations and clearer U.S. drug pricing boost long-term pharma outlook. Leaders like Eli Lilly and Merck lead in GLP-1s, oncology, and pipeline strength.

The reporting duo demonstrate how drugmakers exploit public funding and legal loopholes to turn high profits, while justifying the price tag.

GENEVA (Reuters) -Swiss drugmakers could strike their own deals with the U.S. after President Donald Trump's push to lower prescription drug prices led to an accord with Pfizer in exchange for tariff relief,

Alnylam Pharmaceuticals, Inc. is rated Hold due to high expectations, competitive threats, and revenue expansion. Learn more about ALNY stock here.

ORLANDO, FLORIDA / ACCESS Newswire / October 30, 2025 / RedChip Companies will host an investor webinar with NDT Pharmaceuticals Inc. (OTC PINK:NDTP), a company focused on advancing innovative consumer health and wellness solutions,

Three pharma companies that have delivered the highest average 5-year ROCE are all into manufacturing the same type of products. Explore more to know what is driving these niche pharma players.

But last week, those words took on the force of law. On Tuesday, Texas Attorney General Ken Paxton filed a lawsuit against Kenvue, maker of brand-name Tylenol, directly citing the administration's new "Make America Healthy Again" movement.

Lupin Limited recently commemorated the inauguration of its new corporate offices at 100 Somerset Corporate Blvd in Bridgewater.

AstraZeneca, Eli Lilly and Merck committed $120 million to develop an advanced pharmaceutical manufacturing training center in Central Virginia.

CSPC Pharmaceutical Group ( ($HK:1093) ) just unveiled an update. CSPC Pharmaceutical Group Limited announced that its Executive Director, Mr. Pan

Shares of Vanda Pharmaceuticals fell after the company reported a third-quarter loss that wider than a year ago and dropped the high end of its full-year revenue view. The stock was 18% lower, at $4.43, midday Thursday. The shares have fallen about 7.7% this year, but hit their 52-week high of $5.70 on Tuesday.